Skip to content
MedsAcross

Medicine

Methylprednisolone 200 mg/5 mL injectable suspension

Methylprednisolone · Intralesional, intramuscular, intrasynovial, soft tissue
Available on requestPrescription onlyUS FDAGeneric name

Methylprednisolone 200 mg/5 mL injectable suspension is a generic prescription medicine for intralesional, intramuscular, intrasynovial, soft tissue use, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at controlled room temperature 20°C to 25°C (68°F to 77°F).

Key facts

Active ingredient (INN)
Methylprednisolone
Brand
Sold under the generic name
Strength
200 mg/5 mL
Dosage form
Injectable suspension
Route
Intralesional, intramuscular, intrasynovial, soft tissue
Packs
1 vial of 5 mL, 25 vials of 5 mL
Manufacturer
Gland PharmaIndia
Origin register
US FDA, United States
Storage
Store at controlled room temperature 20°C to 25°C (68°F to 77°F).
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
D07AA01 Methylprednisolone
HS code (indicative)
3004.32Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
2 November 2026
Identifiers
DailyMed set ID cfc2eaf8-7c99-4ce1-95cf-ba1dc0226aedNDC 68083-620Application ANDA219662

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

Packs from every labeler of this generic presentation.

PackCodeLabelerMarketed since
1 vial, multi-dose in 1 carton / 5 mL in 1 vial, multi-dose68083-620-01Gland PharmaIndia2 November 2026
25 vial, multi-dose in 1 carton / 5 mL in 1 vial, multi-dose68083-620-25Gland PharmaIndia2 November 2026
1 vial in 1 carton / 5 mL in 1 vial25021-820-05—15 November 2021
1 vial in 1 carton / 5 mL in 1 vial85766-195-05—1 April 2026

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 24 October 1957Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Methylprednisolone 200 mg/5 mL injectable suspension.

Compare all 2

Other strengths and forms of Methylprednisolone

Clinical summary

Methylprednisolone is a corticosteroid indicated in conditions. It is available as tablets, powder for injection and injectable suspension for intramuscular, intravenous and oral use. MedsAcross supplies Methylprednisolone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Methylprednisolone

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Methylprednisolone 200 mg/5 mL injectable suspension for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.